BR112014027287A2 - sistema de computador, meio capaz de ser lido por computador e método para determinar a eficácia relativa de fármacos anticâncer - Google Patents

sistema de computador, meio capaz de ser lido por computador e método para determinar a eficácia relativa de fármacos anticâncer

Info

Publication number
BR112014027287A2
BR112014027287A2 BR112014027287A BR112014027287A BR112014027287A2 BR 112014027287 A2 BR112014027287 A2 BR 112014027287A2 BR 112014027287 A BR112014027287 A BR 112014027287A BR 112014027287 A BR112014027287 A BR 112014027287A BR 112014027287 A2 BR112014027287 A2 BR 112014027287A2
Authority
BR
Brazil
Prior art keywords
computer system
determining
relative efficacy
optical density
cancer cells
Prior art date
Application number
BR112014027287A
Other languages
English (en)
Inventor
E Hallquist Allan
Perree Mathieu
Petit Olivier
Original Assignee
Diatech Oncology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49514877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014027287(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Diatech Oncology Llc filed Critical Diatech Oncology Llc
Publication of BR112014027287A2 publication Critical patent/BR112014027287A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/59—Transmissivity
    • G01N21/5907—Densitometers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/90—Programming languages; Computing architectures; Database systems; Data warehousing

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Theoretical Computer Science (AREA)
  • Computing Systems (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Databases & Information Systems (AREA)
  • Software Systems (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medical Treatment And Welfare Office Work (AREA)

Abstract

resumo “sistema de computador, meio capaz de ser lido por computador e método para determinar a eficácia relativa de fármacos anticâncer” a presente invenção se refere a um sistema de computador que é proporcionado para determinar a eficácia relativa de fármacos anticâncer. a interface tem opções selecionáveis, incluindo uma opção para gerenciar os parâmetros de teste de fármaco, e permite a seleção por parte do usuário dos parâmetros de teste de fármaco desejados em relação à placa de cavidade virtual associada com a placa de cavidade física de um espectrômetro. o sistema de computador faz com que o espectrômetro inicie um teste de fármaco, em que a placa de cavidade física inclui pelo menos uma cavidade de teste contendo células de câncer viáveis; e pelo menos um candidato de fármaco em uma concentração pré-determinada; e pelo menos uma cavidade de controle contendo as células de câncer viáveis isoladamente. o sistema registra a densidade ótica da cavidade em um pré-determinado comprimento de onda em intervalos de tempo selecionados por uma duração de tempo selecionada, e armazena as medições de densidade ótica e de tempo no banco de dados. um valor de atividade é calculado a partir das medições de densidade ótica e de tempo, e a correlação é exibida entre o valor de atividade e a habilidade do candidato de fármaco para induzir apoptose nas células de câncer. ?? ?? ?? ?? 1/1
BR112014027287A 2012-05-02 2013-05-02 sistema de computador, meio capaz de ser lido por computador e método para determinar a eficácia relativa de fármacos anticâncer BR112014027287A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261641610P 2012-05-02 2012-05-02
US13/803,623 US9476871B2 (en) 2012-05-02 2013-03-14 System and method for automated determination of the relative effectiveness of anti-cancer drug candidates
PCT/US2013/039189 WO2013166233A1 (en) 2012-05-02 2013-05-02 System and method for automated determination of the relative effectiveness of anti-cancer drug candidates

Publications (1)

Publication Number Publication Date
BR112014027287A2 true BR112014027287A2 (pt) 2017-08-08

Family

ID=49514877

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014027287A BR112014027287A2 (pt) 2012-05-02 2013-05-02 sistema de computador, meio capaz de ser lido por computador e método para determinar a eficácia relativa de fármacos anticâncer

Country Status (23)

Country Link
US (3) US9476871B2 (pt)
EP (2) EP4134962A1 (pt)
JP (1) JP6365988B2 (pt)
KR (1) KR102028711B1 (pt)
CN (1) CN104412270B (pt)
AU (2) AU2013256248B2 (pt)
BR (1) BR112014027287A2 (pt)
CA (1) CA2872109C (pt)
CL (1) CL2014002981A1 (pt)
CO (1) CO7190233A2 (pt)
CR (1) CR20140551A (pt)
CU (1) CU20140125A7 (pt)
HK (1) HK1203670A1 (pt)
IL (1) IL235455B (pt)
MX (1) MX345540B (pt)
NI (1) NI201400128A (pt)
NZ (1) NZ702526A (pt)
PE (1) PE20150299A1 (pt)
PH (1) PH12014502687A1 (pt)
RU (1) RU2014148543A (pt)
SG (1) SG11201407141VA (pt)
TW (1) TWI605413B (pt)
WO (1) WO2013166233A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9476871B2 (en) * 2012-05-02 2016-10-25 Diatech Oncology Llc System and method for automated determination of the relative effectiveness of anti-cancer drug candidates
KR20150035537A (ko) * 2012-05-15 2015-04-06 디아테크 온콜로지, 엘엘씨 종양 세포 분리/정제 프로세스 및 이의 사용 방법들
US9460407B2 (en) * 2013-05-03 2016-10-04 Sap Se Generating graphical representations of data
WO2015171848A2 (en) * 2014-05-08 2015-11-12 Diatech Oncology, Llc Synergism and antagonism between multiple anti-cancer agents determined by mick assay
JP6521528B2 (ja) * 2016-04-18 2019-05-29 富士フイルム株式会社 代替医薬品検索装置及び代替医薬品検索方法
US11151604B2 (en) * 2016-06-10 2021-10-19 International Business Machines Corporation Revenue management using dynamic customer selection
CN110047562B (zh) * 2019-05-14 2021-04-27 上海上药第一生化药业有限公司 一种基于酶活力测定法的效价检测的信息化结构和方法
US20200388355A1 (en) * 2019-06-07 2020-12-10 Cary A. Presant Method and devices for direct apoptosis assay of purified cells

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068181A (en) 1989-12-01 1991-11-26 Akzo N.V. Method of monitoring reagent delivery in a scanning spectrophotometer
US5356793A (en) 1990-03-15 1994-10-18 Nitta Gelatin Inc. Method for testing the sensitivity of anticancer drug
US6077684A (en) 1996-11-14 2000-06-20 Vanderbilt University Automated assay for measuring apoptosis in cell culture
CN1220395A (zh) * 1997-12-15 1999-06-23 中国科学院生物物理研究所 一种基于微量元素分布特征的抗癌药物筛选方法
US6448030B1 (en) 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
WO2002040702A2 (en) * 2000-11-09 2002-05-23 Vanderbilt University Methods for the treatment of cancer and other diseases and methods of developing the same
AU2002239771A1 (en) 2000-11-13 2002-06-18 Vanderbilt University Methods of predicting chemotherapy response
WO2002058533A2 (en) 2000-11-17 2002-08-01 Slanetz Alfred E Process for determining target function and identifying drug leads
AU2002238874A1 (en) 2002-03-13 2003-09-22 F.Hoffmann-La Roche Ag Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
US6900058B2 (en) 2003-03-11 2005-05-31 Bionostics, Inc. Control solution for photometric analysis
US8021611B2 (en) * 2005-04-09 2011-09-20 ProteinSimple Automated micro-volume assay system
CN1954887A (zh) * 2005-10-28 2007-05-02 中国科学院大连化学物理研究所 一种体外抗癌药物筛选模型的制备方法
US7736905B2 (en) * 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
KR100721927B1 (ko) 2006-10-31 2007-05-28 이수앱지스 주식회사 암조직에서 암세포를 분리하는 방법
GB2474613A (en) 2008-07-10 2011-04-20 Nodality Inc Methods and apparatus related to management of experiments
US20120224053A1 (en) * 2009-06-17 2012-09-06 Board Of Regents, The University Of Texas System Method and apparatus for quantitative microimaging
KR101533469B1 (ko) 2010-02-03 2015-07-02 연세대학교 산학협력단 Ｒａｓ의 Ｔｈｒ-144번과 Ｔｈｒ-148번의 인산화의 감지를 통한 암 진단 방법, 항암제 스크리닝 및 약효테스트 방법
US20110244503A1 (en) * 2010-03-31 2011-10-06 Perree Mathieu System and Method for Anti-Cancer Drug Candidate Evaluation
US8475739B2 (en) * 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US9476871B2 (en) * 2012-05-02 2016-10-25 Diatech Oncology Llc System and method for automated determination of the relative effectiveness of anti-cancer drug candidates
KR20150035537A (ko) 2012-05-15 2015-04-06 디아테크 온콜로지, 엘엘씨 종양 세포 분리/정제 프로세스 및 이의 사용 방법들

Also Published As

Publication number Publication date
AU2013256248B2 (en) 2018-10-04
US20200249222A1 (en) 2020-08-06
CO7190233A2 (es) 2015-02-19
MX2014013271A (es) 2015-04-08
US9476871B2 (en) 2016-10-25
WO2013166233A1 (en) 2013-11-07
AU2018282460B2 (en) 2020-12-10
CN104412270A (zh) 2015-03-11
EP2847701A4 (en) 2016-01-06
US20140141462A1 (en) 2014-05-22
PH12014502687A1 (en) 2015-01-26
PE20150299A1 (es) 2015-02-25
JP2015524046A (ja) 2015-08-20
AU2018282460A1 (en) 2019-01-24
HK1203670A1 (en) 2015-10-30
CN104412270B (zh) 2018-03-20
CL2014002981A1 (es) 2015-09-11
NI201400128A (es) 2015-11-24
NZ702526A (en) 2017-05-26
KR20150023337A (ko) 2015-03-05
AU2013256248A1 (en) 2015-01-15
US10488402B2 (en) 2019-11-26
IL235455B (en) 2018-03-29
TW201349161A (zh) 2013-12-01
EP4134962A1 (en) 2023-02-15
US20170219563A1 (en) 2017-08-03
CR20140551A (es) 2015-02-23
CA2872109C (en) 2019-08-20
EP2847701A1 (en) 2015-03-18
KR102028711B1 (ko) 2019-10-04
RU2014148543A (ru) 2016-06-27
MX345540B (es) 2017-02-03
CA2872109A1 (en) 2013-11-07
CU20140125A7 (es) 2015-05-28
JP6365988B2 (ja) 2018-08-01
TWI605413B (zh) 2017-11-11
SG11201407141VA (en) 2014-11-27

Similar Documents

Publication Publication Date Title
BR112014027287A2 (pt) sistema de computador, meio capaz de ser lido por computador e método para determinar a eficácia relativa de fármacos anticâncer
Foo et al. Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer
D'amato et al. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
Daugaard et al. Hace1 controls ROS generation of vertebrate Rac1-dependent NADPH oxidase complexes
Yang et al. GSK3β signaling is involved in ultraviolet B-induced activation of autophagy in epidermal cells
Fradley et al. QT prolongation and oncology drug development
BR112017007962A2 (pt) método implementado por computador, aparelho, mídia de armazenamento, programa de computador, kit, e, uso do kit
BR112015031856A8 (pt) Aparelho para prover um regime de dosagem de proteína plasmática terapêutica e dispositivo acessível à máquina
Starkey et al. Intravenous salbutamol for childhood asthma: evidence-based medicine?
Fiala et al. Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation
Rigby‐Jones et al. Propofol and children–what we know and what we do not know
Zang et al. Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
BR112015026601A2 (pt) método para um ensaio de triagem de fármaco à base de células e o uso do mesmo
Shackelford Unravelling the connection between metabolism and tumorigenesis through studies of the liver kinase B1 tumour suppressor
El-Refai et al. Epidemiologic analysis along the mevalonate pathway reveals improved cancer survival in patients who receive statins alone and in combination with bisphosphonates
Frisira et al. NPI-0052 and γ-radiation induce a synergistic apoptotic effect in medulloblastoma
Shao et al. Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
Patel et al. New oral anticoagulants: dosing and monitoring
Zhang et al. Preclinical evaluation of the dual mTORC1/2 inhibitor sapanisertib in combination with cisplatin in nasopharyngeal carcinoma
WO2017167942A8 (en) Method for predicting the response of melanoma patients to a medicament
Lindgren et al. Genome wide expression analysis of radiation-induced DNA damage responses in isogenic HCT116 p53+/+ and HCT116 p53−/− colorectal carcinoma cell lines
Biswas et al. Novel Cellular functions of ATR for therapeutic targeting: embryogenesis to Tumorigenesis
Liu et al. RETRACTED ARTICLE: The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials
Tham et al. Does saturable formation of gemcitabine triphosphate occur in patients?
BR112021019398A2 (pt) Método implementado por computador, sistema para determinar um risco relativo e produto de programa de computador

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: G06F 19/00

Ipc: G01N 33/50 (2006.01), G01N 21/59 (2006.01), G16C 2

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]